| Oct 22 |
ABVC BioPharma receives $50,000 in incremental licensing fees, shares climb
|
| Oct 22 |
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
|
| Aug 16 |
ABVC BioPharma GAAP EPS of -$0.09
|
| Aug 15 |
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
|
| Jul 2 |
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
|
| Jun 25 |
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
|
| Jun 21 |
ABVC Biopharma files to sell 1M shares of common stock for holders
|
| Jun 12 |
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
|
| May 24 |
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
|
| May 22 |
ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M
|
